Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
Kleinpell
Ruth
R
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000209:etiology; D003422:Critical Care / Q000379:methods; D004730:Endothelium, Vascular / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D009102:Multiple Organ Failure / Q000209:etiology; D011486:Protein C / Q000627:therapeutic use*; D020151:Protein C Deficiency / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use*; D018805:Sepsis / Q000150:complications / Q000188:drug therapy* / Q000451:nursing / Q000503:physiopathology
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated